Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today that Roche Diagnostics will return full rights for a Tamoxifen treatment response and breast cancer molecular classification test to Epigenomics, which will undertake sole development of the test. This tissue-based test, designed to predict the probability of disease recurrence in breast cancer patients, was part of a multi-product collaboration with Roche Diagnostics. Epigenomics and Roche Diagnostics will continue to collaborate on the development of three screening products for colon, prostate and breast cancers.
